Publications
30
Citations
352
Est. group size
—
Recurring co-author estimate
Active years
10
Publishing since 2016
Typically publishes in teams of ~14 · 10% small-team papers (≤3 authors) · across 10 venues
- POSTER: ALL-300 Unusual Hepatic Involvement in Acute Lymphoblastic Leukemia: A Case Report
Clinical Lymphoma Myeloma & Leukemia · 2025
- Abstract PO5-19-08: Neoadjuvant HER2-targeted Therapy +/- Immunotherapy with Pembrolizumab (neoHIP): An Open Label Randomized Phase II Trial
Cancer Research · 2024
- Neoadjuvant HER2-targeted therapy ± immunotherapy with pembrolizumab (neoHIP): An open label randomized phase II trial.
Journal of Clinical Oncology · 2023
- Supplementary Data from A Phase Ib Study of Preoperative, Locoregional IRX-2 Cytokine Immunotherapy to Prime Immune Responses in Patients with Early-Stage Breast Cancer
2023
- Supplementary Data from A Phase Ib Study of Preoperative, Locoregional IRX-2 Cytokine Immunotherapy to Prime Immune Responses in Patients with Early-Stage Breast Cancer
2023
- Data from A Phase Ib Study of Preoperative, Locoregional IRX-2 Cytokine Immunotherapy to Prime Immune Responses in Patients with Early-Stage Breast Cancer
2023
- Data from A Phase Ib Study of Preoperative, Locoregional IRX-2 Cytokine Immunotherapy to Prime Immune Responses in Patients with Early-Stage Breast Cancer
2023
- Elacestrant and the Promise of Oral SERDs
Journal of Clinical Oncology · 2022
- Multiplex immunofluorescence to measure dynamic changes in tumor-infiltrating lymphocytes and PD-L1 in early-stage breast cancer
Breast Cancer Research · 2021
- A Case Series of Metastatic Metaplastic Breast Carcinoma Treated With Anti-PD-1 Therapy
Frontiers in Oncology · 2021
- Abstract 1665: QuPath versus InForm: Digital image analysis of multiplex immunofluorescence (mIF) tumor-infiltrating lymphocyte (TIL) outcomes in an immunotherapy clinical trial
Cancer Research · 2021
- 398 neoIRX: a phase II trial of locoregional cytokine therapy to promote immunologic priming and clinical response to neoadjuvant pembrolizumab plus chemotherapy in triple negative breast cancer (TNBC)
Regular and Young Investigator Award Abstracts · 2021
- Abstract P6-10-09: Multispectral immunofluorescence (mIF) to detect dynamic changes in PD-L1 expression, immune cell (IC) infiltration, and tumor-IC interactions in primary breast cancer (BC) immuno-oncology (I-O) clinical trials
Cancer Research · 2020
- Concordance of multispectral immunofluorescence (mIF) with programmed death ligand 1 (PD-L1) and stromal tumor infiltrating lymphocyte (sTILs) clinical assays in early-stage breast cancer (BC).
Journal of Clinical Oncology · 2020
- Immunotherapy Toxicities
Surgical Oncology Clinics of North America · 2019
- Journal of Clinical Oncology×6
- Cancer Research×5
- Gastroenterology×1
- Breast Cancer Research×1
- Frontiers in Oncology×1
- Shreya Kumar
Medicine · Purdue University West Lafayette
- Jonathan E. Schoenhals
Medicine · The Ohio State University
- Scott A. Hammond
Medicine · The Ohio State University
- Joseph Azar
Medicine · The Ohio State University
- Tarah J. Ballinger
Medicine · Indiana University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 25, 2026.
Claim or correct this profile